DALLAS, Jan. 4, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Keryx Biopharmaceuticals (Nasdaq:KERX). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/KERX
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Keryx Biopharmaceuticals (KERX) focuses on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Its products under development include Zerenex, an oral iron-based compound is in phase II clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease in the United States and Japan; and KRX-0401, an oral anti-cancer agent in phase II clinical development.
Message Board Search for KERX: http://www.boardcentral.com/boards/KERX
In the report, the analyst notes:
"KERX recently initiated a phase III registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed and refractory multiple myeloma patients. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. This trial is being conducted pursuant to a special protocol assessment (SPA) with the FDA. Additionally, the FDA has granted perifosine orphan drug and fast track designations in this indication. "
"On December 2, the Company announced it received FDA Fast Track designation for KRX-0401(perifosine) for the treatment of relapsed/refractory multiple myeloma, significantly reducing the FDA review time of a new drug application, and therefore can expedite the time to market for perifosine in multiple myeloma."
To read the entire report visit: http://www.beaconequity.com/i/KERX
See what investors are saying about KERX at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.